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Poxvirus infection has a strong effect on cellular functions. To understand viral pathogenesis, it is necessary to know how viral proteins
interact with host proteins. The B1R kinase is an early viral gene required for vaccinia virus DNA synthesis and replication, but no cellular
substrate is known for this viral kinase. B1R is able to hyperphosphorylate p53 in several residues in the N-terminal transactivation domain,
including Ser15 and Thr18. B1R does not phosphorylate Mdm2. B1R promotes an increase in p53 ubiquitination and a reduction of p53
acetylation by p300. The over-expressed B1R protein induces the degradation of p53 in a concentration-dependent manner and is lost when
Ser15 and Th18 are changed to alanine or when the B1R kinase is inactivated by introducing the K149Q substitution. The B1R-induced
downregulation of p53 requires Mdm2. The hyperphosphorylated p53 is transcriptionally active, and this activity also falls as B1R increases.
The BAX gene promoter is more sensitive to this reduction of transcription than p21 or 14-3-3 gene promoters. This effect of B1R on p53 can
be one of the mechanisms by which vaccinia virus exerts its role in infected cells.
D 2004 Elsevier Inc. All rights reserved.
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Viral proteins might alter cellular proteins and, inde-
pendently of their role in the viral life cycle, contribute to
the pathogenesis; these interactions may be selected in
evolution to permit viable virus–host cell systems, and thus
be incorporated as a viral strategy to guarantee its survival.
Poxviruses, which include smallpox and vaccinia viruses,
have a large DNA of 191 kb (Moss, 1990), thus during
infection the replication of the viral DNA to make an
infected particle is likely to be a major burden for the cell. It
is therefore possible that because of its needs, during
evolution, these viruses acquired strategies to manipulate
the host cell biology to their advantage. Furthermore, other0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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E-mail address: plazozbi@usal.es (P.A. Lazo).unrelated viruses use strategies based on their interaction
with p53, as is the case with SV40 (Zhen et al., 1999),
adenovirus (Wienzek et al., 2000), or papillomaviruses
(Thomas et al., 1999), thus there is no reason why vaccinia
virus should not have a strategy of its own to act on p53.
The levels of p53 play a role in the control of the cell cycle
and apoptosis (Levine, 1997; Ljungman, 2000; Prives and
Hall, 1999; Sherr and McCormick, 2002). Most studies on
vaccinia are focused on viral life cycle biology, without
considering the potential effects that individual viral
proteins might have on cellular proteins, which may not
be necessary for viral life cycle, but can contribute to the
viral pathogenesis. Some authors have detected a decrease
of p53 protein level immediately after infection (Wali and
Strayer, 1999).
In the cell, the p53 protein levels are held under tight
control by binding to Mdm2, which promotes its ubiquiti-
nation and subsequent proteolytic degradation. The inter-
action between p53 and Mdm2 is regulated by
phosphorylation of p53 in its N-terminus. These phosphor-04) 254–265
C.R. Santos et al. / Virology 328 (2004) 254–265 255ylations affect the p53 interaction with Mdm2 and as a
consequence stabilize the p53 protein and regulate its
transcriptional role. Phosphorylation of p53 has been
studied mainly in the context of the cellular response to
genotoxic damage (Levine, 1997; Prives and Hall, 1999;
Vousden and Lu, 2002). Some phosphorylation sites in p53
N-transactivation domain have been shown to interfere with
p53 binding to Mdm2, and thus promote its transcriptional
role (Dumaz and Meek, 1999). Particularly, Thr18 is critical
for binding of p53 to Mdm2 and its phosphorylation disrupt
the interaction (Schon et al., 2002) by destroying a critical
hydrogen bond (Jabbur et al., 2002; Kussie et al., 1996).
Because viral replication occurs within few hours after
infection, any effect relating both components will have to
be mediated by a fast response mechanism, such as
phosphorylation. Therefore, a likely mechanism will be that
an early viral kinase and a cellular protein, regulated by
phosphorylation and with an effect on cell cycle control,
could be implicated.
The viral proteins implicated in such a process are
likely to be coded by early viral genes. In vaccinia virus
life cycle, the early expression of the B1R gene coding for
a kinase is necessary for viral DNA replication (Banham
and Smith, 1992; Lin et al., 1992; Rempel and Traktman,
1992). The expression of B1R protein takes place before
viral DNA synthesis (Banham and Smith, 1992; Lin et al.,
1992). Because B1R is present in the virions, upon
infection, it can have an immediate effect on cellular
substrates before any additional effect on transcription is
noticeable. Little is known about the substrates of the B1R
kinase, among them is the H5R viral protein (Beaud et al.,
1995; Brown et al., 2000), also known as the VLTF4
transcription factor (Kovacs and Moss, 1996; Kovacs et
al., 2001), but nothing is known regarding other cellular or
viral protein substrates, except the phosphorylation of
some ribosomal proteins (Banham et al., 1993). The p53
molecule is a key regulator of the G1 to S transition.
Therefore, we hypothesized that p53 might be a target of
the B1R kinase, since its human homolog VRK1 is
capable of phosphorylating p53 (Barcia et al., 2002;
Lopez-Borges and Lazo, 2000), ATF2 (Sevilla et al.,
2004b), and c-Jun (Sevilla et al., in press).
In this report, we have shown that B1R is capable of
hyperphosphorylating p53, leading to its downregulation by
an Mdm2-dependent mechanism. The B1R kinase is a
potential target for therapies directed to control infection by
members of the vaccinia virus family.Results
B1R phosphorylates p53
To demonstrate that B1R can modulate p53, first we
studied if B1R could phosphorylate either p53 or Mdm2.
For this aim, a GST–p53 (murine) fusion protein containingresidues 11–63 (FP279) (Fig. 1A) was used as substrate.
The Mdm2 binding region is conserved in human and
murine p53 proteins; human Ser15 and Thr18 are equivalent
to murine Ser18 and Thr21, respectively. The p53 T18Awas
tested because the human homolog VRK1 phosphorylates
this residue (Lopez-Borges and Lazo, 2000). At the same
time, it was also determined if B1R could phosphorylate
p53 additional residues in other parts of the molecule. For
this purpose, three GST–human p53 constructs were used, a
full-length (1–393), central DNA binding domain (90–290)
and a C-terminus (290–393) GST fusion proteins (Fig. 1A).
Minor phosphorylation was detected in the carboxy terminal
domain (residues 290–393), but it was more than 10-fold
lower than that of the amino-terminus (Fig. 1A). The
phosphorylation of murine and human p53 is similar and the
apparently higher phosphorylation of the murine protein
with respect to the human is a consequence of the different
number of protein targets employed in the assay since for
the same amount of protein, there are 7.5 murine molecules
(52 amino acids) for each human molecule (393 amino
acids). There is also some autophosphorylation of the B1R
molecule (Banham and Smith, 1992; Lin et al., 1992;
Rempel and Traktman, 1992). The phosphorylation is
specific for the p53 moiety, and B1R does not phosphorylate
Mdm2 in the p53 interaction domain, used a GST–Mdm2
fusion protein (residues 1–188) (Fig. 1B). This p53 N-
terminal region, the Mdm2 binding site, is identical in
humans and mouse. Also a substitution, K149Q, was
introduced in the catalytic site of B1R to generate an
inactive kinase. The inactive kinase B1R (K149Q) was not
able to phosphorylate p53 (Fig. 1C).
To determine the affinity of the B1R kinase for p53 as
substrate, a kinetic analysis of the reaction was performed
using different concentrations of GST–p53. The vaccinia
kinase B1R has a Km for p53 of approximately 1 AM.,
which is well suited to the intracellular concentrations of
p53 (Fig. 1D).
The B1R kinase phosphorylates p53 in several residues
including Ser15 and Thr18
To identify the p53 residues phosphorylated by B1R,
fusion proteins GST–p53 (FP221, residues 1–85) containing
substitutions of all phosphorylatable residues were studied
in an in vitro kinase assay. However all of the individual p53
mutants in its N-terminus (S15I, T18A, S20A, S34A, S55A,
and S61A) were phosphorylated, suggesting that more that
one residue was targeted by B1R (not shown). Therefore, to
identify the phosphorylated residues a phosphoaminoacid
analysis was performed. This analysis showed that at least
two residues were phosphorylated since radioactivity was
incorporated in both phosphoserine and phosphothreonine
positions (not shown).
In view that more than one residue was phosphorylated,
we proceeded to analyze the phosphopeptide map of
phosphorylated p53 and individual p53 mutants in each
Fig. 1. Phosphorylation of p53 by vaccinia B1R. (A) In vitro B1R kinase assay using as substrates of the GST–B1R kinase, both GST–murine p53 (11–
63, FP279), GST–human p53 (1–390, 90–290 and 290–390). To separate GST from p53, the fusion protein was digested with thrombin after
phosphorylation. The control has only the GST–B1R protein and no substrate. (B) Phosphorylation of the p53 moiety of the GST–p53 fusion protein and
lack of phosphorylation of Mdm2. (C) The p53 phosphorylation requires an active B1R kinase, since the inactive B1R (K149Q) mutant does not
phosphorylate p53. In the left panel is shown the protein staining with Coomassie blue and in the right panel is the incorporation of radioactivity in the
kinase assay. (D) Kinetics of the affinity of B1R kinase for p53. Different amounts (Ag) of GST–p53 (FP221: fusion protein with residues 1–85) in a
volume of 50 Al were used as substrate of the GST–B1R kinase (1 Ag). The concentration was calculated taking into account the molecular weight of the
fusion protein. The quantifications of the bands were performed during the linear response range of the incorporation of radioactivity and of the detection
system.
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p53 fusion protein (FP279 with residues 11 to 63) was used,
as well as mutants with substitutions of Ser15, Thr18 and
Ser20 to Ala (Fig. 2). At least four phosphopeptide were
labeled, and some were lost in the case of some sub-stitutions, such as for S15I and T18A mutants, permitting
the identification of at least two of the phosphorylated
residues. Therefore, it was concluded that at least three
residues in the N-terminus of p53 are targets for phosphory-
lation by B1R.
Fig. 2. Identification of some p53 residues phosphorylated in vitro by B1R
kinase. Phosphopeptide map of the wild type GST–p53 fusion protein
(FP279) and three mutants in the p53 moiety. The arrows indicate the
phosphopeptide spots that disappear in the mutants.
Fig. 3. Subcellular localization of the B1R protein in H1299 cells
transfected with the expression plasmid pSG–HA–B1R. The B1R protein
was detected with a combination of an antibody against the HA epitope and
a secondary antibody labeled with Cy2. Nuclei were identified by DNA
staining with DAPI.
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types
The B1R kinase does not have any known protein
signature regarding its potential subcellular localization.
Therefore, we proceeded to determine its location inside
the cell. For this purpose, H1299 cells were transfected
with an eukaryotic expression vector containing B1R
tagged in its N-terminus with the HA-epitope, plasmid
pSG-HA-B1R, and the location of the expressed protein
was determined with a monoclonal antibody specific for
the HA epitope. Similar results were obtained with both
cell lines. The transfected B1R protein is located diffusely
in the cytoplasm, but there is also a significant amount
within the nucleus, as shown by its colocalization with
DAPI staining (Fig. 3). In this experiment, the transfection
efficiency is approximately 60%, since of the 15 cells in
the field (stained with DAPI), only 9 present green
fluorescence (presence of B1R). In the two cells (the two
with the greenest intensity) where there was overexpres-
sion of B1R, some of this B1R protein was also detectable
in the cytosol.
B1R phosphorylates p53 in vivo promoting its
ubiquitination and reducing its acetylation
To demonstrate that B1R can also phosphorylate p53
inside the cell, H1299 cells were transfected with B1R and
p53, using 0.5 Ag/ml of adryamicin as a positive control. In
whole cell extracts from the transfected cells, it was
determined that Ser15 was phosphorylated in the presence
of B1R using an antibody specific for this Ser15 phosphor-
ylation of p53 (Fig. 4A). Phosphorylation of p53 in Thr18
could not be determined because of the lack of a suitable
antibody. This result indicates that the phosphorylation can
also occur in vivo.
The consequence of p53 phosphorylation might be to
alter its interaction with its covalent modification systems,
which might have opposite effects. Ubiquitination will
favor its degradation and acetylation will promote itsstability and transcriptional activity (Brooks and Gu, 2003;
Li et al., 2002; Wang et al., 2004). Therefore, we tested if
ubiquitination of p53 was increased by B1R. This experi-
ment was performed in the presence of the proteasome
inhibitor MG132. B1R results in an increase in p53
ubiquitination (Fig. 4B). Next, we determined if B1R
could affect acetylation. In these experiments, the cells
were also cotransfected with plasmid. The presence of
B1R significantly reduced the acetylation of p53 by p300
(Fig. 4B).
B1R downregulates the levels of p53
Phosphorylation of p53 can alter the stability of the p53
protein. To determine if the B1R kinase has any effect on
the p53 molecule in the cell, we first determined the effect
of B1R, or the inactive kinase B1R (K149Q) on the
endogenous levels of p53. For this aim, we used a cell
line, MCF7 that has a wild type p53 endogenous protein.
In these cells, the amount of endogenous p53 protein
decreased as the amount of transfected B1R plasmid and
corresponding protein was increased (Fig. 5A), suggesting
that this effect might be a consequence of promoting p53
downregulation, but the effect was lost when using the
inactive kinase. To quantify this effect, the stability of the
endogenous p53 molecules in the presence of B1R was
determined. MCF7 cells were transfected with the empty
vector or with the plasmid expressing B1R, afterwards
cycloheximide was added to the culture and the level of
p53 determined at several time points. The inclusion of
B1R reduced p53 stability manifested as a reduction of its
half-life from 93 to 56 min in these experimental
conditions (Fig. 5B).
To confirm this observation on p53 stability, we used a
cell line that is null for p53, the colon carcinoma H1299 cell
line. In this cell line a fixed amount of wt p53, 100 ng of
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amounts of pSG-HA-B1R plasmid or its inactive form with
the K149Q mutation. As shown in Fig. 5C, as B1R protein
increased, there was a decrease in the level of transfected
p53, which is consistent with the observation made with the
endogenous protein in MCF7 cells. To show that the effect
on p53 required an active B1R kinase, the same experiment
was performed using an expression construct of B1R with
the K149Q substitution. This inactive B1R kinase (K149Q)
did not induce p53 downregulation (Fig. 5), suggesting its
direct participation in this effect.Mutation of p53 phosphorylatable residues affects the
B1R-induced p53 downregulation
The intracellular p53 level is controlled by the p53–
Mdm2 interaction, necessary for p53 ubiquitination, and
the p53–Mdm2 interaction is modulated by phosphoryla-
tion. Therefore, next, it was tested if the substitution of
some of the residues targeted by B1R on the p53
molecule could alter the effect on p53 downregulation.
The substitutions for alanine of the p53 residues, S15 and
T18, in the p53 helix region needed for binding to
Mdm2 were tested in H1299 cells. The design of the
experiment is similar to that of the wild type p53. The
substitution of these two residues by themselves or in
combination resulted in the loss of the downregulation
induced by B1R (Fig. 6). These data indicate that the
p53 region that interacts with Mdm2 was implicated in
the B1R effect.
The effect of B1R on p53 requires Mdm2
Because p53 degradation is promoted by ubiquitination
mediated by Mdm2, it was decided to test if in a cell line
lacking Mdm2, the effect was still detectable. For this
purpose, murine embryo fibroblasts, derived from p53 and
Mdm2 double-null mouse (Montes de Oca Luna et al.,
1995), were used. In this cell line, transfected B1R was
unable to induce the degradation of wild type p53 by
hyperphosphorylation (Fig. 7A top), obtaining a result
similar to that obtained by transfection with the p53T18A
mutant (Fig. 7A bottom). This indicates that the effect on
p53 is likely to be dependent on the presence of Mdm2.
Therefore, to test if that is correct, a similar experiment
was performed, but in the transfection a plasmid-express-
ing Mdm2 (pCOC-Mdm2) was included. When Mdm2
was reintroduced, B1R also induced the degradation ofFig. 4. In vivo effect of B1R on p53 phosphorylation, ubiquitination, and
acetylation. (A) Detection of p53 phosphorylation in vivo. H1299 were
transfected with 0.2 Ag pCB6 + p53 and 4.8 Ag of pSG-HA plasmid alone
or with HA-B1R construct and subject to western blot with specific
antibodies to detect p53 phosphorylated in Ser15 or total protein. No
transfected cells and cells treated with 0.5 Ag/ml adriamycin for 6 h (ADR
are shown as controls. (B) Effect of B1R on p53 ubiquitination. H1299 cells
were transfected with 1 Ag of pCB6 + p53 expression plasmid together with
plasmids encoding for pCOC-Mdm2 (2 Ag) and pSG-HA plasmid alone o
with HA-B1R construct (4 Ag). One microgram of plasmid encoding
Ubiquitin was added in all cases. Twenty-five micromolar of the
proteasome inhibitor MG132 was added 24 h after transfection for 6 h
where indicated, after which whole cells extracts were prepared and
analyzed by Western blot. P53 was detected with a mix of monoclona
antibodies DO-1 and Pab1801. The ubiquitinated form of p53 is indicated
C. Effect of B1R on p53 acetylation by p300. At the bottom is shown the
relative levels of acetylated versus non-acetylated p53. H1299 cells were
transfected with pCB6+p53 (0.2 Ag), pCMVp300-HA (2 Ag) and 5.8 Ag o
pSG-HA plasmid alone or with HA-B1R construct as indicated in the
legend. The transfected p53 was immunoprecipitated using monoclona
antibodies and the blot analyzed for the acetylation of p53 on Lys 373 and
382 with a specific antibody.t
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clear when the T18A substitution is introduced (Fig. 7B
bottom), but that is similar to the experiment in cells
containing Mdm2 (Fig. 7B). The quantification of the
relative changes in levels for the p53 wild type and T18A
mutant in the absence or presence of Mdm2 is shown in
Fig. 7C. B1R in the absence of Mdm2 is able to promote
p53 accumulation, independently of the T18A substitu-
tion, this may be due to the effect on other interactions,which become detectable when the major degradation
system, mdm2, is absent. Among these are included other
recently described proteins such as PirH2 (Leng et al.,
2003) and COP1 (Dornan et al., 2004). The hyper-
phosphorylated p53 molecule is destined for downregula-
tion when Mdm2 is present.
The p53 phosphorylated by B1R is transcriptionally active
on some promoters
Since p53 is a transcription factor, it is possible that this
role is also affected by the B1R kinase. If that is the case, the
activation of p53-dependent transcription in the presence of
B1R should also decrease consistently with the reduction in
p53 protein level. To test this effect, H1299 cells were
transfected with a reporter plasmid containing a synthetic
p53 response element with the luciferase gene reporter,
plasmid p53-luc. The transfection of increasing amounts of
pSG-HA-B1R plasmid resulted in a reduction of the p53-
dependent transcription as the amount of B1R was increased
(Fig. 8A). Therefore, the effect of B1R on p53 can have
functional consequences since it can be reflected at the level
of gene transcription. The reduction in p53 level is
accompanied by the corresponding reduction in transcrip-
tional activity.
To determine if there was a differential effect depending
on the type of promoter responding to p53, several
promoters were studied, such as p21, Bax, Mdm2, and 14-
3-3, all of them coupled to a luciferase gene. The
transfection was performed in the presence of 200 ng of
p53 and with 2 Ag of pSG-HA-B1R. The results in relative
values are shown in Fig. 7B. The reporter with the synthetic
promoter responded as expected. However, among the gene-
specific promoters, the bax promoter appears to be the most
sensitive to the p53 phosphorylation by B1R (Fig. 8B). To
further confirm this observation, the levels of the cellular
bax protein were determined in A549 cells transfected with
increasing amounts of pSG-HA-B1R. As shown in Fig. 8C,Fig. 5. Effect of B1R on the levels of p53 proteins in different genetic
backgrounds. (A) MCF7 cells (p53 wt) were transfected with differen
amounts of pSG-HA-B1R or its inactive mutant pSG-HA-B1R (K149Q
and the levels of different proteins determined by immunoblot with the
corresponding antibody. To the right is shown the quantification of the
immunoblot. (B) MCF7 cells (p53 wt) were transfected with 3 Ag of pSG
HA vector or with the pSG-HA-B1R construct. Twenty-four hours afte
transfection, cycloheximide was added to the cultures and the levels of p53
protein at different time points were determined by Western blot. The
quantitation of p53 protein levels, normalized with h-actin is shown. The
straight lines represent the linear regression adjustment of the individua
time points. (C) Transfection of H1299 cells (p53 null) with pSG-HA-B1R
or its inactive mutant pSG-HA-B1R (K149Q) and 100 ng of pCB6+p53
The cells were lysed for analysis 24 h after transfection. The level of p53
was normalized with respect to the actin level. The quantification of the
effect of the kinase on p53 is shown in the panel below the immunoblots
The mean of three independent experiments with duplicate determinations
are shown with their standard deviation. * P b 0.05.t
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Fig. 6. Effect of B1R on different amino acid substitutions in the p53
molecule. Three different p53 amino acid changes were studied. The
response in levels of the p53 substitutions S15A (A), T18A (B), and S15/
T18A (C) were studied as a function of the response to increasing amounts
of B1R in transfected H1299 cells (p53 null). The level of p53 was
normalized with respect to the actin level.
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the bax protein.Discussion
During evolution of virus–host cell interaction, first a
viral protein must modify a cellular protein, and afterwards
this interaction is modulated by biological selection to
generate a viable system that will permit viral survival
without compromising the host. Therefore, the analysis of
individual viral and cellular protein effects are a conse-
quence of this selection and is useful to identify individual
components that led to a viable virus–host cell ecosystem.
In this report, we have demonstrated that hyperphosphor-
ylation of p53 by the vaccinia B1R kinase results in its
downregulation. Most of the phosphorylations appear to
occur in the p53 N-terminus, where several residues are
phosphorylated; however, there is also an additional
phosphorylation in the tetramerization domain (Fig. 1).
Hyperphosphorylation is a characteristic of casein kinase I,
which phosphorylates residues located three to fiveresidues from a negative charge (Flotow and Roach,
1991), and a phosphorylated residue promotes the phos-
phorylation of proximal Ser or Thr residues (Flotow et al.,
1990). Thus, the hyperphosphorylating activity of B1R is a
likely reflection of its evolutionary origin from VRK
proteins, a branch of the CKI group (Manning et al.,
2002). The p53 phosphorylation pattern by B1R is more
complex than that of its human homolog VRK1. VRK1 is
more restricted and specific for Thr18 residue (Lopez-
Borges and Lazo, 2000). Interestingly, B1R phosphorylates
p53, but not Mdm2, thus any effect on this pair of proteins
have to be a consequence of the p53 modification. For the
interaction of p53 and Mdm2, the p53 region comprised
between residues 15–23 is essential, this region forms a
helix that is stabilized by a hydrogen bond between Thr18
and Asp21 (Jabbur et al., 2002; Schon et al., 2002).
Phosphorylation of Thr18 disrupts the interaction, and the
logical consequence will be a stabilization of p53.
However, phosphorylation by B1R results in p53 degra-
dation, despite phosphorylation in Thr18. This may be due
to the complexity of the structure of the N-terminus region,
where the three residues, Ser15, Thr18, and Ser20, have
important effects on transcription, stability, and degrada-
tion, Ser15 is more important for transcription than for
Mdm2 binding (Dumaz and Meek, 1999), and Ser20
appears to facilitate Mdm2-dependent degradation (Dumaz
et al., 2001). The dual phosphorylation of Ser15 and Thr18
by B1R may also perhaps have a similar effect. There
might also be a contribution of the phosphorylation of p53
in its C-terminus (Fig. 1), which is weaker because
probably only one residue is phosphorylated. Phosphor-
ylation in the C-terminus domain may interfere with p53
tetramerization (Sakaguchi et al., 1997), which thus is not
able to function as a transcription factor. Phosphorylation
of p53 in its C-terminus by protein kinase C is known to
facilitate p53 ubiquitination and degradation (Chernov et
al., 2001). The downregulation of p53 by B1R is clearly
dependent on the requirement for Mdm2. When Mdm2 is
absent, the effect is the opposite, that is, accumulation, but
when Mdm2 is reintroduced in the Mdm2 null cells, the
effect of B1R is restored.
Downregulation of p53 protein by a viral gene product
makes sense in the context of viral biology. Since p53 can
trigger apoptosis in response to viral infection, and thus
contribute to abort it, it is reasonable to expect that during
evolution viruses developed strategies to avoid such a
response. The demonstration that vaccinia B1R kinase
affects the tumor suppressor p53, adds another virus that
employ cellular p53 as a strategy in the infectious cycle.
Other viruses where interactions between viral proteins and
cellular p53 have been demonstrated are human papilloma-
viruses, SV40 or adenovirus. (Ashcroft et al., 2000; Shieh et
al., 1997; Siliciano et al., 1997). The phosphorylation of p53
by the B1R kinase links the viral life cycle of vaccinia to
that of other viruses in the sense of sharing a mechanism
able to regulate the cell cycle in the G1 phase, although the
Fig. 7. The effect of B1R on p53 requires Mdm2. (A) Transfection of murine embryo fibroblasts (p53 and Mdm2 null) with pSG-HA-B1R and 100 ng of pCB6
+ p53 or pCB6 + p53T18A. (B) Reintroduction of Mdm2. In the same cells, identical experiment as in A is performed but including the mammalian expression
vector pCOC-Mdm2. (C) Quantification of the effect on p53 without (black) or with Mdm2 (grey), the level of p53 was normalized with respect to the actin
level. The values were calculated using the top panels of A and B for wild type p53, and the lower panel of A and B for p53T18A.
C.R. Santos et al. / Virology 328 (2004) 254–265 261objective is different, DNA repair in the case of the cell, and
viral replication in the viral infection. A downregulation of
p53 could promote synthesis of DNA, and that has been
reported in cells infected with vaccinia virus (Wali and
Strayer, 1999). Furthermore, downregulation of p53 would
also prevent p53-mediated responses, such as apoptosis
(Manfredi, 2003; Shen and White, 2001). Microarray
analysis of gene expression in vaccinia virus-infected cells
has shown that p53 is not downregulated at the transcrip-
tional level (Guerra et al., 2003, 2004). The consequence of
downregulation of p53 is a reduction of p53-dependent
transcription, particularly of the bax gene promoter, a
protein that induces apoptosis (Shen and White, 2001),
which is also reflected at the bax protein level. Vaccinia
virus lacks genes with homology to bcl-2 proteins; however,
it does have inhibitory effects on apoptosis. This inhibition
of the apoptosis mitochondrial pathway has been associated
with some viral proteins as F1L (Wasilenko et al., 2001,
2003) or E3L and K3L (Fang et al., 2001). Therefore, an
effect mediated by downregulation of bax expression is well
suited to reduce apoptosis in vaccinia virus-infected cells.
In all cases, a viral strategy based on p53 implies that it is
a late evolutionary aspect. In the case of vaccinia, its
precursors must have acquired the gene from the VRK gene
family. The VRK family of kinases forms a group thatdiverged from the branch that led to the casein kinase
family, thus sharing a common ancestor (Manning et al.,
2002). Because the human and murine genomes have three
VRK genes, and there are poxviruses specific for each of
these two species, the precursor poxvirus must have
acquired the gene that resulted in the B1R kinase before
mammalian divergence took place. Because of the con-
servation of the human VRK1 and B1R catalytic domains
(Wali and Strayer, 1999), it is highly likely that VRK1 could
complement the phenotypes caused by B1R inactivation,
such as viral DNA replication. The replacement of B1R by
VRK1 in a vaccinia virus defective with a defective B1R is
able to rescue the mutation and permit viral replication
(Boyle and Traktman, 2004). This rescue must be due to a
shared specificity between B1R and VRK1; however, it
requires extremely high levels of VRK1 protein, since the
endogenous level of VRK1 does not rescue the mutant.
Once the kinase was acquired, the viral kinase gene
diverged on its own. In this regard, it is important to note
that B1R has a C-terminus with a role not yet known, and
unrelated to mammalian VRK proteins (Lopez-Borges and
Lazo, 2000; Nichols and Traktman, 2004), but that is highly
likely to play an important role in viral biology, probably by
mediating interactions with other cellular or viral proteins
that remain to be identified.
Fig. 8. (A) Effect of B1R on p53-dependent transcription. H1299 cells (p53/) were transfected with 200 ng of pCB6+p53 and variable amounts of pSG-HA-
B1R. The luciferase activity of the p53-luc plasmid was determined 12 h after transfection and normalized by the internal control the Renilla-luciferase (phRL-
tk) activity. (B) Transfection of H1299 cells with 200 ng of pCB6+p53 and 2 Ag of pSG-HA-B1R using as reporters luciferase constructs of different genes
responding to p53, such as p21, bax, Mdm2, and 14-3-3. The values were compared with the construct using the synthetic p53 promoter under identical
conditions. In all experiment, the mean of three independent experiments with duplicate determinations are shown with their standard deviation. * P b 0.05. (C)
Reduction in the cellular level of bax protein in A549 cells that were transfected with different amounts of pSG-HA-B1R. The bax protein was detected with a
specific monoclonal antibody.
C.R. Santos et al. / Virology 328 (2004) 254–265262The vaccinia B1R kinase can be an important therapeutic
target for control of viral infections by members of the
vaccinia virus family. The B1R kinase and its homolog in
smallpox virus are good targets for therapeutic intervention
by using kinase inhibitors. This is particularly important
now that smallpox has been eradicated, and as consequence
this type of drug would be necessary in the control of anacute outbreak that might occur by whatever reason, natural,
or deliberate.
It is very likely that understanding the effects of B1R on
cell biology is much more complex that just an effect on
p53, but this observation opens up a new way to look at the
role of this early viral protein in the pathogenesis of vaccinia
infection. Also, understanding the biology of vaccinia virus
C.R. Santos et al. / Virology 328 (2004) 254–265 263is important because it is being used as a delivery vehicle for
some gene therapy protocols.Material and methods
GST–B1R fusion protein cloning, purification, and kinase
assay
To purify the vaccinia B1R kinase a fusion protein with
glutathione-S-transferase was made. The B1R sequence was
synthesized by PCR with forward primer (5V-CCGGATC-
CATGAACTTTCAAGGACTTGTGTTAAC-3V) and
reverse primer (5V-CCGTCGACTTAATAATATACACCC-
TGCATTAATA-3V). As substrate, we used clone pAB6
kindly provided by G. Smith (Imperial College, London,
UK) (Banham and Smith, 1992). The PCR product was
subcloned in plasmid pCR2.1 (Invitrogen, Carlsbad, CA)
and sequenced. The B1R coding sequenced was subcloned
into the BamHI and SalI restriction sites fused in frame with
the GST sequence in plasmid pGEX-4T1 (Amersham
Biosciences, Little Chalfont, and UK). The fusion GST–
B1R protein was induced with IPTG and purified with
Sepharose-glutathione beads (Amersham Biosciences).
Inactive kinase, both in fused to GST or in an expression
plasmid was obtained by introducing the K149Q substitu-
tion into the kinase active site by site-directed mutagenesis
using the Quick-Change mutagenesis kit (Stratagene, San
Diego, CA).
The kinase activity in vitro was determined by assaying
protein phosphorylation in a mixture containing 20 mM
Tris–HCl, pH 7.5, 5 mM MgCl2, 0.5 mM dithiothreitol, 150
mM KCl and 5 AM (5 ACi) g-32P-ATP with 1 Ag of GST–
B1R protein and 10 Ag of another protein as substrate when
indicated. The reaction was routinely performed for 2 h at
30 8C. The reaction products were analyzed by SDS-
polyacrylamide gel electrophoresis. For the kinetic analysis,
the reaction conditions were similar with the exception that
the amount of GST–p53 varied as indicated in the
corresponding experiment. Always the reaction was per-
formed in the linear response phase of incorporation of
radioactivity. Quantitation was performed by two different
techniques, direct quantitation in a BioRad personal
phosphorimager, or by exposure to X-ray film, in their
linear response range and quantitation of the bands by
densitometry. With both methods, the same result was
obtained, where the Vmax was always determined in
arbitrary units as pixels per surface area unit.
GST–p53 fusion proteins and mutants
The different GST–p53 murine fusion proteins, full-
length FP221 (residues 1–85) and FP 279 (residues 11–63)
were obtained from David Meek (Dundee University,
Scotland). Additional point mutations were introduced in
Ser or Thr residues to obtain multiple mutations and havebeen described (Lopez-Borges and Lazo, 2000). GST
constructs with human p53, full-length residues 90–290
and 290–393 were from Tony Kouzarides (Cancer Research
UK, Cambridge). The GST–Mdm2 (1–188) protein was a
gift of A. Levine (Rockfeller University).
Expression of B1R protein tagged with the HA epitope
For transfection experiments in mammalian cells the
sequence coding for B1R was subcloned in vector pSG5L-
HA (Stratagene) with restriction sites EcoRI and BamHI.
The clone, named pSG5L-HA-B1R, was confirmed by
DNA sequencing. Plasmids were prepared with the JetStar
maxiprep kit from Genomed (Bad Oeynhausen, Germany).
Acid hydrolysis and phosphoaminoacid analysis
A phosphorylation reaction was performed with the
GST–B1R protein and GST–p53 as substrate. Autophos-
phorylated proteins were fractionated in a SDS-PAGE gel
and transferred to an Immobilon-P membrane (Millipore,
Bedford, MA). The band with the phosphorylated protein
was cut, incubated with 0.5% polyvinyl-pyrrolidone in 100-
mM acetic acid for 30 min at 37 8C, followed by extensive
washes with water and fresh 50 mM NH4HCO3. The
membrane was incubated twice, with 10 Ag of trypsin
(Roche Diagnostics, Mannheim, Germany) in 50 mM
NH4HCO3, pH 8.0 for 2 h at 37 8C, and a third time for
18 h. The membrane was extensively washed with sterile
distilled water. The washes were freeze-dried, and oxidized
with 9:1 performic acid/hydrogen peroxide for 1 h at room
temperature, followed by freeze-drying. The sample was
resuspended in 5 Al of formic acid: acetic acid: water
(1:3.12:35.88) pH 1.9 and applied to a chromatoplaque
(Merck, Darmstadt, Germany). The first dimension was an
electrophoresis at 1.5 kV for 90 min in a Multiphor system
(Pharmacia, Uppsala, Sweden). The plaque was left to air
dry, and turned. The second dimension was a chromatog-
raphy performed in acetic acid: pyridine: n-butanol/water
(1:3.33:5:4) for 13 h (Lopez-Borges and Lazo, 2000). The
radioactivity on the plate was analyzed with a BioRad FX
Molecular Imager (BioRad, Hercules, CA) or exposed to X-
ray film.
Cell culture and transfections
The cell lines used were H1299 (p53/), MCF7 or
mouse embryo fibroblasts from double p53/Mdm2 knock
out mice (G. Lozano, MD Anderson Cancer Center,
Houston). H1299 and MCF7 cells were grown in RPMI
supplemented with 10% foetal calf serum, penicillin and
streptomycin. 293T cells and fibroblasts were grown in
DMEM. The cells were lysed in lysis buffer (Tris–HCl 50
mM pH 8, 150 mM NaCl, 5 mM EDTA and 1% Triton X-
100 plus protease and phosphatase inhibitors) or acetylation
immunoprecipitation lysis buffer (50 mM HEPES, pH 7.8,
C.R. Santos et al. / Virology 328 (2004) 254–265264200 mM NaCl, 1% (v/v) Triton X-100, 10 mM EDTA, 5
mM DTT, 5 AM trichostatin A and protease and phosphatase
inhibitors).
The ubiquitin tagged with the His epitope (clone BRR12-
his-Ubiquitin) was from S. Lain and D. Lane (Dundee
University, Scotland). Plasmid pCMV-p300-CHA was from
Richard Eckner (University of Zurich, Switzerland). Plas-
mids pCB6+p53, pCB6-P53T18A and pCOC-Mdm2 were a
gift from K. Vousden (Beatson Institute, Glasgow, UK).
Also reporter constructs pBAX-luc, p21-luc and p14-3-3-
Luc, containing the promoter of the p53 responsive genes
linked to luciferase, were used (from M. Oren, Rehovot,
Israel). The indicated cell lines were transfected with the
JetPEI reagent from Polytransfection (Illkirch, France)
according to manufacturer’s instructions.
Immunofluorescence and confocal microscopy
H1299 cells were plated on 10-cm2 dishes (5  105)
containing 1-cm-diameter sterile glass cover slips and
transiently transfected as described; 24 h posttransfection,
the slides were transferred to a tissue culture test plate. After
washing with PBS they were fixed in 4% paraformaldehyde
in PBS for 30 min at room temperature. Next, the cells were
permeabilized in cold PBS containing 0.2% Triton X-100
for 30 min and then treated with glycine 10 mM for 10 min
at room temperature. The cells were blocked with a solution
containing 1% bovine serum albumin in PBS, at room
temperature for 30 min, and then incubated for 30 min at 37
8C or 1 h at room temperature with an anti-HA antibody in
blocking solution. The cells were washed three times with
PBS 0.1% Triton X-100 and incubated with a goat anti-
mouse Cy2-labeled antibody (Amersham Biosciences) in
blocking solution. The cells were washed three times with
PBS 0.1%, Triton X-100 and stained with DAPI (4V, 6V-
diamidino-2-phenylindol) Sigma (St. Luis, MO) 1:1000 in
PBS for 10 min at room temperature. The cells were washed
three times with PBS, and slides were mounted with
Gelvatol (Monsanto). Subcellular localization was analyzed
with a Zeiss LSM 510 confocal microscope.
Luciferase reporter assays
Transcription activity was determined using different
reporter constructs with the luciferase gene. As internal
control the phRL-tk plasmid (Promega, Madison, WI) was
used for normalization. Luciferase assays were performed
using a dual luciferase reporter kit (Promega). Lumines-
cence was determined with a MiniLumat LB9506 lumin-
ometer (Berthold, Bad Wildbad, Germany).
Antibodies for immunoblots
The product of tagged transfected B1R was detected
with a monoclonal antibody against the HA epitope from
Covance (Berkeley, CA). The human p53 protein wasdetected with a mixture of DO1 and Pab1803 antibodies
(Santa Cruz, CA). In acetylation assay, immunoprecipita-
tion of p53 was performed using a mix of the anti p53
monoclonal antibodies DO-1 and Pab240 (1 Ag each) and
GammaBind G Sepharose (Amersham Biosciences). A
rabbit antiserum from Upstate Biotechnology (Lake Placid,
NY) detecting specifically acetylated p53 in Lys373 and
382 was used. To detect endogenous p53 Ser15 phosphor-
ylation in vivo, specific rabbit polyclonal antibodies from
Santa Cruz were used. Bax protein was detected with a
monoclonal antibody from Santa Cruz. The anti h-actin
antibody was from Sigma. A Goat anti-mouse-HRP and
Goat anti-rabbit-HRP (Amersham Pharmacia Biotech) were
used at 1:10000 in Western Blots. For analysis, 50 Ag of
whole cell extracts was loaded in the gel. Proteins
fractionated in SDS-polyacrylamide gels were transferred
to Immobilon-P membranes (Millipore) and the immuno-
blots were developed with the ECL detection reagents
(Amersham Biotech).Acknowledgments
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